Manpreet Rattan
Family · Fort Worth, TXNPI 1831722412
Payments from drug & device makers
Across 98 payments — averaging $19.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$556
- Pfizer$285
- AstraZeneca$127
- Lilly USA, LLC$123
- Corcept Therapeutics$103
- Novartis$93
- plus $589 from 15 others
What the payments were for
- Food & beverage$1,867100%
- Education$90%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 34 | $556 |
| Pfizer | 14 | $285 |
| AstraZeneca | 8 | $127 |
| Lilly USA, LLC | 7 | $123 |
| Corcept Therapeutics | 4 | $103 |
| Novartis | 4 | $93 |
| AbbVie | 3 | $83 |
| Inari Medical, Inc. | 3 | $76 |
| Dexcom, Inc. | 3 | $71 |
| Lundbeck LLC | 3 | $70 |
| Bayer | 3 | $57 |
| Amgen | 2 | $32 |
| Mallinckrodt Hospital Products Inc. | 1 | $30 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $29 |
| Xeris Pharmaceuticals, Inc. | 1 | $26 |
| Hologic Sales And Service, LLC | 1 | $23 |
| Globus Medical | 1 | $22 |
| Si-bone, Inc. | 1 | $20 |
| Astellas Pharma US Inc | 1 | $20 |
| Exact Sciences | 1 | $16 |
| Organon | 1 | $14 |
How this compares
$1,876 in reported general payments places this provider in the 80th percentile of 15,456 family providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 11 | $24,692 |
| FarxigaDapagliflozin Propanediol | 11 | $13,577 |
| EliquisApixaban | 12 | $12,180 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $2,774 |
| Epinephrine | 11 | $1,710 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 38 | $1,431 |
| Omega-3 Acid Ethyl Esters | 11 | $1,390 |
| Fluticasone Propionate | 43 | $576 |
| Gabapentin | 38 | $493 |
| Atorvastatin Calcium | 49 | $475 |
| Hydralazine Hcl | 29 | $315 |
| Omeprazole | 21 | $295 |
| Hydrochlorothiazide | 36 | $266 |
| Rosuvastatin Calcium | 24 | $262 |
| Ondansetron Hcl | 25 | $260 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $556 | $24,69211 claims |
| AstraZenecaFarxiga | $127 | $13,57711 claims |
| PfizerEliquis | $285 | $12,18012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 15,456 family providers in Texas.
Other family in Fort Worth
- Laura MoeFort Worth$158K
- Julie TaylorFort Worth$63K
- Ryan BourgeoisFort Worth$37K
- Lashonda CraneHouston$3.4M
- David WeirDallas$959K
- Luba YammineHouston$479K
- Robin BeachHouston$428K
- Nirupama JeromeAustin$418K
- April LopezMcAllen$417K
- Linda MercadoHouston$211K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.